Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 4 Interventional

Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression

NCT02141776
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial direct current stimulation (t-DCS), Sham Controlled Arm
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation (tDCS) Therapy in Major Depression

NCT04507243
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active - HD tDCS, Sham - HD tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 15, 2026, 7:53 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 4 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
escitalopram, bupropion, imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

NCT02196506
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Placebo + ADT, Brexpiprazole +ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Beverly Hills, California • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

NCT01739933
View directory record Official record
Conditions
Sepsis, Delirium, Impaired Cognition
Interventions
Dexmedetomidine, Propofol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
11
States / cities
San Francisco, California • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 15, 2026, 7:53 PM EDT
Recruiting No phase listed Observational

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

NCT01403402
View directory record Official record
Conditions
Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)), Alpha-Dystroglycanopathy (Fukuyama CMD), Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I)), Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K)), Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M)), Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N)), Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O)), Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T)), Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U)), Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related), Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB)), Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS)), Choline Kinase B Receptor - CHKB, Collagen VI Related Disorders, Collagen XII Related Disorders, Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive), Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID), Congenital Muscular Dystrophy With Joint Hyperlaxity, Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1, Emery-Dreifuss Muscular Dystrophy, GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement, LMNA Related Disorders, Merosin Deficient CMD (Full or Partial), Nesprin Related MD (SYNE1), SELENON Related Disorders (Previously Known as SEPN1), SELENON Related Myopathy (Aka SEPN1), Telethonin CMD, Congenital Myasthenic Syndrome, Limb-Girdle Muscular Dystrophy, LGMDD01 - DNAJB6 (Formerly LGMD1D), LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant), LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G), LGMDR08 - TRIM Related (Formerly LGMD2H), LGMDR09 - FKRP Related (Formerly LGMD2I), LGMDR10 - Titin (TTN) Related (Formerly LGMD2J), LGMDR11 - POMT1 Related (Formerly LGMD2K), LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M), LGMDR14 - POMT2 Related (Formerly LGMD2N), LGMDR15 - POMGnT1 Related (Formerly LGMD2O), LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P), LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q), LGMDR18 - TRAPPC11 Related (Formerly LGMD2S), LGMDR19 - GMPPB Related (Formerly LGMD2T), LGMDR20 - ISPD Related (Formerly LGMD2U), LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive), LGMDR23 - LAMA2 Related, LGMDR24 - POMGnT2 Related
Interventions
Not listed
Lead sponsor
Cure CMD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 15, 2026, 7:53 PM EDT
Completed No phase listed Observational

Neuroimaging Study for Decoding Emotional States and Identifying Neural Circuits to Disengage From Negative Thinking

NCT06254144
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
functional magnetic resonance imaging (fMRI)
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

NCT04753164
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
ACT-539313, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional

Preventing Long Term Psychiatric Disability Among Those With Major Burn Injuries

NCT00988104
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Mood Disorders, Sleep Disorders
Interventions
Cognitive Behavioral Therapy, Supportive Counseling
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Food Effect Study of LY03005

NCT03822065
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional

Study of Technology-assisted Treatment of Adolescent Depression

NCT01582581
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Telephonic CBT, Wait List Control
Behavioral
Lead sponsor
iHope Network, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Farmington, Connecticut • Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional

A Comparison of Cognitive and Dynamic Therapy for Depression in Community Settings

NCT01207271
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Therapy, Supportive-Expressive Psychodynamic Therapy
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 4 Interventional Results available

Developing New Clinical Management Strategies

NCT02082392
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional Results available

Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression

NCT03363919
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NeuroStar TMS Therapy® System, NeuroStar XPLOR®
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yoga for Persons With Severe Visual Impairment

NCT01366677
View directory record Official record
Conditions
Sleep Disturbance, Stress, Anxiety, Depression, Balance Impairment
Interventions
Yoga Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 15, 2026, 7:53 PM EDT
Recruiting Phase 4 Interventional

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

NCT05450432
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Esketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Rapid Antidepressant Effects of Yohimbine in Major Depression

NCT00078715
View directory record Official record
Conditions
Depression, Involutional, Major Depresssion
Interventions
Yohimbine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 15, 2026, 7:53 PM EDT
Not listed Not applicable Interventional

Reading Remediation and Outcomes in Detention

NCT03261076
View directory record Official record
Conditions
Specific Learning Disorder (MeSH Unique ID: D000067559), Dyslexia (MeSH Unique ID: D004410), Conduct Disorder (MeSH Unique ID: D019955)
Interventions
Strategies Enhancing Reading in Older Underperf. Students
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

NCT02158533
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
High Dose ALKS 5461, Low Dose ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Carson, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

NCT05376150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
XEN1101 10 mg, XEN1101 20 mg, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
20
States / cities
Anaheim, California • Lafayette, California • Pico Rivera, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression

NCT01732055
View directory record Official record
Conditions
Partner Assisted Interpersonal Psychotherapy, Treatment as Usual
Interventions
Partner-Assisted Interpersonal Psychotherapy, Treatment as Usual
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 15, 2026, 7:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cortical GABA Concentrations in Insomnia

NCT00765752
View directory record Official record
Conditions
Insomnia, Major Depression
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
25 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 15, 2026, 7:53 PM EDT